Biotech Stock Surges on Study Results

DiaMedica Therapeutics Inc. (CVE:DMA), a biotech stock, powered higher after announcing positive results from its Phase Ib bridging trial

Sean Mason | March 13, 2017 | SmallCapPower

Positive study results likely made many investors in biotech stock feel a little better Monday. Here’s some small stocks making big moves on Monday, March 13, 2017 (as of 4 pm EST):

Biotech stock DiaMedica Therapeutics Inc. (TSXV: DMA) jumped 26% to $0.27 after announcing what it called “positive results” from its Phase Ib bridging trial, designed to compare the profile of DM199 to the approved urinary KLK1 product on the market in Asia for acute ischemic stroke.

Win Big With Our Small Cap Picks


As well, shares of Aralez Pharmaceuticals Inc. (TSX: ARZ) slid 29% to $3.33 as the specialty pharmaceutical company said its GAAP net loss for fiscal 2016 widened to $103.0 million from $37.8 million during fiscal 2015.

Gran Colombia Gold Corp. (TSX: GCM), meanwhile, reported results of a small underground infill drilling program to explore the extension of the mineralization in the Marmato Underground mine, which included 8.98 metres of 20.99 g/t gold. Gran Colombia Gold stock moved up 6% to $0.095 following the announcement.

Finally, Adamera Minerals Corp. (TSXV: ADZ) gained 16% to $0.11 after the gold explorer announced that it has defined a second set of VTEM electromagnetic anomalies in the Cooke Mountain Project in Washington State. Adamera has now defined six targets that warrant testing during its upcoming drill program.

See more Small and Micro Cap Market Movers Daily from Sean Mason. Tomorrow’s big stock market winners could be found here today!

Hi, did you know SmallCapPower accepts blog submissions? You can contact me here